291 related articles for article (PubMed ID: 28272775)
1. Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.
Pan Y; Shi J; Ni W; Liu Y; Wang S; Wang X; Wei Z; Wang A; Chen W; Lu Y
J Cell Mol Med; 2017 Sep; 21(9):2129-2139. PubMed ID: 28272775
[TBL] [Abstract][Full Text] [Related]
2. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
[TBL] [Abstract][Full Text] [Related]
3. Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling.
Li S; Wang H; Hong L; Liu W; Huang F; Wang J; Wang P; Zhang X; Zhou J
Cancer Biol Ther; 2015; 16(1):176-84. PubMed ID: 25482936
[TBL] [Abstract][Full Text] [Related]
4. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
Hall BA; Kim TY; Skor MN; Conzen SD
Breast Cancer Res Treat; 2012 Sep; 135(2):469-79. PubMed ID: 22842983
[TBL] [Abstract][Full Text] [Related]
5. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
6. Cryptotanshinone inhibits cellular proliferation of human lung cancer cells through downregulation ofIGF-1R/PI3K/Akt signaling pathway.
Zhang J; Wen G; Sun L; Yuan W; Wang R; Zeng Q; Zhang G; Yu B
Oncol Rep; 2018 Nov; 40(5):2926-2934. PubMed ID: 30106122
[TBL] [Abstract][Full Text] [Related]
7. Ampelopsin suppresses breast carcinogenesis by inhibiting the mTOR signalling pathway.
Chang H; Peng X; Bai Q; Zhou Y; Yu X; Zhang Q; Zhu J; Mi M
Carcinogenesis; 2014 Aug; 35(8):1847-54. PubMed ID: 24861637
[TBL] [Abstract][Full Text] [Related]
8. Hexachlorobenzene induces cell proliferation and IGF-I signaling pathway in an estrogen receptor alpha-dependent manner in MCF-7 breast cancer cell line.
García MA; Peña D; Alvarez L; Cocca C; Pontillo C; Bergoc R; de Pisarev DK; Randi A
Toxicol Lett; 2010 Feb; 192(2):195-205. PubMed ID: 19879930
[TBL] [Abstract][Full Text] [Related]
9. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.
Li H; Pan GF; Jiang ZZ; Yang J; Sun LX; Zhang LY
Acta Pharmacol Sin; 2015 May; 36(5):606-13. PubMed ID: 25864647
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor binding protein-4 and -5 modulate ligand-dependent estrogen receptor-α activation in breast cancer cells in an IGF-independent manner.
Hermani A; Shukla A; Medunjanin S; Werner H; Mayer D
Cell Signal; 2013 Jun; 25(6):1395-402. PubMed ID: 23499909
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
13. The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells.
Becker MA; Ibrahim YH; Cui X; Lee AV; Yee D
Mol Endocrinol; 2011 Mar; 25(3):516-28. PubMed ID: 21292829
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
[TBL] [Abstract][Full Text] [Related]
15. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.
Martin EC; Rhodes LV; Elliott S; Krebs AE; Nephew KP; Flemington EK; Collins-Burow BM; Burow ME
Mol Cancer; 2014 Oct; 13():229. PubMed ID: 25283550
[TBL] [Abstract][Full Text] [Related]
16. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
Fukui F; Hayashi SI; Yamaguchi Y
J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
[TBL] [Abstract][Full Text] [Related]
17. Amplified in Breast Cancer Regulates Transcription and Translation in Breast Cancer Cells.
Ochnik AM; Peterson MS; Avdulov SV; Oh AS; Bitterman PB; Yee D
Neoplasia; 2016 Feb; 18(2):100-10. PubMed ID: 26936396
[TBL] [Abstract][Full Text] [Related]
18. Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation.
Chen W; Luo Y; Liu L; Zhou H; Xu B; Han X; Shen T; Liu Z; Lu Y; Huang S
Cancer Prev Res (Phila); 2010 Aug; 3(8):1015-25. PubMed ID: 20628002
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PI3K/AKT molecular pathway mediated by membrane estrogen receptor GPER accounts for cryptotanshinone induced antiproliferative effect on breast cancer SKBR-3 cells.
Shi D; Zhao P; Cui L; Li H; Sun L; Niu J; Chen M
BMC Pharmacol Toxicol; 2020 May; 21(1):32. PubMed ID: 32357920
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV
Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]